Navigation Links
GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
Date:12/13/2011

ATLANTA, Dec. 13, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ("the Company") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, announced that the first patient has been inoculated in the Phase 1/2 clinical trial for the Company's HIV/AIDS therapeutic vaccine.  This is the first study using GeoVax Labs' vaccines for the treatment of persons who are HIV infected.

The protocol for the Phase 1/2 clinical trial will carefully monitor safety while evaluating the ability of the vaccine to elicit protective immune responses in vaccinated participants.  The trial is based on the achievement of post-vaccine viral control in animal studies conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University.

Robert McNally, Ph.D., President and CEO of GeoVax Labs, stated, "Dosing the first study participant marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial.  These three trial sites are actively seeking persons who are interested in and fit the criteria for the study."

To be eligible for the study, persons should have started drugs within 18 months of their last HIV negative test.  Persons who have been infected within the past 18 months, but not started drugs, are also eligible for recruitment into the study.  The first participant was enrolled at the AIDS Research Consortium of Atlanta.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines u
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GeoVax Phase 2a Clinical Trial Completes Enrollment
2. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
3. GeoVax Labs, Inc. Announces Second Quarter Financial Results
4. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
5. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
6. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
7. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
8. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
9. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
10. GeoVax Labs Engages The Investor Relations Group
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... July 31, 2014 Catylix, Inc. ( ... ( Milpitas, California ) announced today ... and commercialize new fluorination products and related chemistry. ... benefited from the use of substituents that are ... with polarity to improve binding and bioavailability. Fluorinated ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:8/1/2014)... Online retailer Disposable Medical Express has ... guarantee on their inventory of Tranquility incontinence care products. ... pads along with other personal care products. , ... a line of incontinence products that you love,” a ... works for you, you shouldn't have to compromise because ...
(Date:8/1/2014)... Stress management can be difficult in this ... concentration and diminish rest and leisure time, stress can mount ... to find a way to manage stress in order to ... “Having a good sense of work-life balance is the key ... founding clinician of SF Custom Chiropractic. “Stress, left unchecked, can ...
(Date:7/31/2014)... Just in time for Washington’s unusually ... is featuring new summertime drink specials on their famed ... locations throughout the season. , A longtime ... customer-nominated Seattle’s best happy hour is well-known for its ... Union location’s 25th anniversary this summer, Duke is now ...
(Date:7/31/2014)... you have asthma, you may have an asthma action plan ... respond to changes and understand when symptoms are getting worse ... you,re doing well, yellow means your asthma has worsened and ... New guidelines are now available to help your allergist steer ... away from the red zone. , "Management of acute loss ...
(Date:7/31/2014)... The 2013 PolyU TSI hit a record ... in 2012. The index measures inbound tourists’ satisfaction ... into an overall index. The 2013 index indicates ... Hong Kong over time. , The index shows ... in Hong Kong are attractions (79.27) and transportation ...
Breaking Medicine News(10 mins):Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... -- Could injecting a gene into a patient with ... Physician-scientists are setting out to answer that question in ... severe heart failure. , NewYork-Presbyterian Hospital/Columbia University Medical ... City area where the therapy is currently available. , ...
... will develop training standards and guidelines to ensure ... keeps pace with growth ... To develop first-of-its-kind,guidelines and training standards for ... disease, the Society for,Cardiovascular Angiography and Interventions (SCAI) ...
... Plans to build a second state-of-the-art CCRC across ... MATTHEWS, N.C., June 18 ACTS Retirement-Life,Communities has ... parcel,located near the intersection of Fullwood Lane and ... to add approximately 350 independent,living apartments and single ...
... U.K. study suggests , , WEDNESDAY, June 18 (HealthDay News) ... of anticipating how people might behave during a psychotic ... University of Cambridge, found that patterns of normal brain ... , The researchers compared the brain activity of 15 ...
... in Nation,s 4th Leading Cancer Killer, BETHPAGE, ... Cancer Research, the largest private foundation dedicated,exclusively to ... Request For Proposals (RFP) to identify promising research ... deaths in the United,States., The Lustgarten Foundation,s ...
... the National ... Injury Prevention Program, WASHINGTON, June ... Safety for Seniors Act of 2008,and urges lawmakers to provide ... Center to fully implement this critical,fall prevention initiative., "Millions ...
Cached Medicine News:Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 3Health News:ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina 2Health News:Brain Activity May Predict Schizophrenia Behavior 2Health News:Lustgarten Foundation Announces 2009 Request for Proposals (RFP) 2Health News:Samarion Praises Congress for Passage of Safety for Seniors Act of 2008 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: